𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia

✍ Scribed by Evelien L. J. Smits; Cindy Lee; Nicola Hardwick; Suzanne Brooks; Viggo F. I. Van Tendeloo; Kim Orchard; Barbara-ann Guinn


Publisher
Springer-Verlag
Year
2011
Tongue
English
Weight
243 KB
Volume
60
Category
Article
ISSN
0340-7004

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Relevance of clinical trials in acute my
✍ Apostolia M. Tsimberidou; Elihu Estey πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 57 KB

## Abstract Patients with newly diagnosed acute myeloid leukaemia (AML) are increasingly being enrolled in clinical trials sponsored by pharmaceutical companies or the National Cancer Institute. These trials routinely exclude patients who are less likely to respond (LLTR), e.g. those with Zubrod pe

Clofarabine in the treatment of poor ris
✍ Janusz Krawczyk; Naeem Ansar; Ronan Swords; Tracy Murphy; Barry MacDonagh; Teres πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 92 KB

## Abstract Clofarabine is a second generation nucleoside analogue. It inhibits DNA repair and activates the mitochondrial apoptotic pathway leading to cell death. __In vitro__ clofarabine has demonstrated synergy with daunorubicin and Ara‐C and in phase II clinical trials has shown promising activ

Acute leg ischaemia as a presentation of
✍ Mataix, Rodolfo; GΓ³mez-Casares, M. Teresa; Campo, Conrado; JimΓ©nez, Santiago; Ma πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 126 KB πŸ‘ 2 views

a manifestation of lymphoma, and all died before receiving chemotherapy. If a patient with WM develops ascites, clinicians should consider the possibility that the disease has transformed into IL, especially if the patient has received alkylating agents.